Frank Leu PhD

Frank Leu is a co-founder and CEO of Novapeutics at Philadelphia, PA - a biopharma spun-out from the University of Pennsylvania, developing a first-in-class small molecule beta-cell restoration curative for the type 2 diabetes. Prior, Frank was at a specialty pharma, Verto Institute, developing antibody therapeutics for neuroendocrine cancer. Frank holds a doctorate degree in Pharmacology from the Weill Cornell Graduate School of Medical Sciences and performed his posdoctoral work at a Howard Hughes Medical Institute lab at the Rockefeller University.

Frank also founded BioPharMatrix, an advisory firm providing pragmatic vision and intelligence in the area of Lifesciences; such as working with 1776 (formerly Benjamins Desk) on shaping, developing and running of the Pennovation Center’s biopharma laboratories at the University of Pennsylvania.